the last omnicar data was presented in Paris earlier this year, showing that the in vivo rest phase greatly improved efficacy in the mouse model. I thought this announcement was hugely underrated. Not only does this give important information with regards to how to design an optimal omnicar clinical trial, it also can only be achieved with our platform, which improves the chances that this will be a tipping point that an early developer in the space will go down the omnicar road instead of persisting developing their own car-t program.
hardly nothing.
PTX Media related, page-1370
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.3¢ |
Change
-0.001(2.27%) |
Mkt cap ! $34.62M | |||
| Open | High | Low | Value | Volume |
| 4.3¢ | 4.3¢ | 4.3¢ | $15.15K | 352.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 223984 | 4.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.5¢ | 411380 | 5 |
View Market Depth
| Last trade - 10.06am 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
4.5¢ |
Change
-0.001 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 4.3¢ | 4.5¢ | 4.3¢ | 37550 | ||
| Last updated 11.29am 17/05/2024 ? | |||||
| PTX (ASX) Chart |